×
S&P 500   3,825.33 (+1.06%)
DOW   31,097.26 (+1.05%)
QQQ   282.13 (+0.66%)
AAPL   138.93 (+1.62%)
MSFT   259.58 (+1.07%)
META   160.03 (-0.76%)
GOOGL   2,174.75 (-0.21%)
AMZN   109.56 (+3.15%)
TSLA   681.79 (+1.24%)
NVDA   145.23 (-4.20%)
NIO   21.36 (-1.66%)
BABA   116.00 (+2.04%)
AMD   73.67 (-3.66%)
MU   53.65 (-2.95%)
CGC   2.81 (-1.40%)
T   21.31 (+1.67%)
GE   63.54 (-0.20%)
F   11.32 (+1.71%)
DIS   96.14 (+1.84%)
AMC   13.53 (-0.15%)
PFE   52.31 (-0.23%)
PYPL   71.40 (+2.23%)
NFLX   179.95 (+2.91%)
S&P 500   3,825.33 (+1.06%)
DOW   31,097.26 (+1.05%)
QQQ   282.13 (+0.66%)
AAPL   138.93 (+1.62%)
MSFT   259.58 (+1.07%)
META   160.03 (-0.76%)
GOOGL   2,174.75 (-0.21%)
AMZN   109.56 (+3.15%)
TSLA   681.79 (+1.24%)
NVDA   145.23 (-4.20%)
NIO   21.36 (-1.66%)
BABA   116.00 (+2.04%)
AMD   73.67 (-3.66%)
MU   53.65 (-2.95%)
CGC   2.81 (-1.40%)
T   21.31 (+1.67%)
GE   63.54 (-0.20%)
F   11.32 (+1.71%)
DIS   96.14 (+1.84%)
AMC   13.53 (-0.15%)
PFE   52.31 (-0.23%)
PYPL   71.40 (+2.23%)
NFLX   179.95 (+2.91%)
S&P 500   3,825.33 (+1.06%)
DOW   31,097.26 (+1.05%)
QQQ   282.13 (+0.66%)
AAPL   138.93 (+1.62%)
MSFT   259.58 (+1.07%)
META   160.03 (-0.76%)
GOOGL   2,174.75 (-0.21%)
AMZN   109.56 (+3.15%)
TSLA   681.79 (+1.24%)
NVDA   145.23 (-4.20%)
NIO   21.36 (-1.66%)
BABA   116.00 (+2.04%)
AMD   73.67 (-3.66%)
MU   53.65 (-2.95%)
CGC   2.81 (-1.40%)
T   21.31 (+1.67%)
GE   63.54 (-0.20%)
F   11.32 (+1.71%)
DIS   96.14 (+1.84%)
AMC   13.53 (-0.15%)
PFE   52.31 (-0.23%)
PYPL   71.40 (+2.23%)
NFLX   179.95 (+2.91%)
S&P 500   3,825.33 (+1.06%)
DOW   31,097.26 (+1.05%)
QQQ   282.13 (+0.66%)
AAPL   138.93 (+1.62%)
MSFT   259.58 (+1.07%)
META   160.03 (-0.76%)
GOOGL   2,174.75 (-0.21%)
AMZN   109.56 (+3.15%)
TSLA   681.79 (+1.24%)
NVDA   145.23 (-4.20%)
NIO   21.36 (-1.66%)
BABA   116.00 (+2.04%)
AMD   73.67 (-3.66%)
MU   53.65 (-2.95%)
CGC   2.81 (-1.40%)
T   21.31 (+1.67%)
GE   63.54 (-0.20%)
F   11.32 (+1.71%)
DIS   96.14 (+1.84%)
AMC   13.53 (-0.15%)
PFE   52.31 (-0.23%)
PYPL   71.40 (+2.23%)
NFLX   179.95 (+2.91%)
NASDAQ:XNCR

Xencor Stock Forecast, Price & News

$28.86
+1.49 (+5.44%)
(As of 07/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$27.22
$29.07
50-Day Range
$19.74
$28.86
52-Week Range
$19.35
$43.61
Volume
411,605 shs
Average Volume
364,134 shs
Market Capitalization
$1.72 billion
P/E Ratio
16.21
Dividend Yield
N/A
Price Target
$52.33

Xencor Stock Forecast (MarketRank)

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
81.3% Upside
$52.33 Price Target
Short Interest
Bearish
5.36% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.24
Upright™ Environmental Score
News Sentiment
0.45mentions of Xencor in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.62) to ($2.55) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.28 out of 5 stars

Medical Sector

321st out of 1,429 stocks

Pharmaceutical Preparations Industry

131st out of 682 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive XNCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xencor and its competitors with MarketBeat's FREE daily newsletter.

Xencor logo

About Xencor (NASDAQ:XNCR)

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. Its product candidates include Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. In addition, it is developing VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19. Further, the company is developing AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.

XNCR Stock News Headlines

Xencor (NASDAQ:XNCR) Downgraded by StockNews.com to "Sell"
Xencor (NASDAQ:XNCR) Hits New 12-Month Low at $20.75
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:XNCR
Employees
254
Year Founded
N/A

Company Calendar

Last Earnings
5/05/2022
Today
7/01/2022
Next Earnings (Estimated)
8/03/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$52.33
High Stock Price Forecast
$60.00
Low Stock Price Forecast
$42.00
Forecasted Upside/Downside
+81.3%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
8 Analysts

Profitability

Net Income
$82.63 million
Pretax Margin
33.28%

Debt

Sales & Book Value

Annual Sales
$275.11 million
Cash Flow
$1.71 per share
Book Value
$12.54 per share

Miscellaneous

Free Float
57,024,000
Market Cap
$1.72 billion
Optionable
Optionable
Beta
0.81














Xencor Frequently Asked Questions

Should I buy or sell Xencor stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Xencor stock.
View analyst ratings for Xencor
or view top-rated stocks.

What is Xencor's stock price forecast for 2022?

8 Wall Street research analysts have issued 1-year price targets for Xencor's stock. Their XNCR stock forecasts range from $42.00 to $60.00. On average, they anticipate Xencor's stock price to reach $52.33 in the next year. This suggests a possible upside of 81.3% from the stock's current price.
View analysts' price targets for Xencor
or view top-rated stocks among Wall Street analysts.

How has Xencor's stock price performed in 2022?

Xencor's stock was trading at $40.12 at the start of the year. Since then, XNCR shares have decreased by 28.1% and is now trading at $28.86.
View the best growth stocks for 2022 here
.

When is Xencor's next earnings date?

Xencor is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Xencor
.

How were Xencor's earnings last quarter?

Xencor, Inc. (NASDAQ:XNCR) announced its quarterly earnings results on Thursday, May, 5th. The biopharmaceutical company reported $0.39 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.70) by $1.09. The biopharmaceutical company had revenue of $85.50 million for the quarter, compared to the consensus estimate of $26.17 million. Xencor had a trailing twelve-month return on equity of 15.74% and a net margin of 33.28%. The firm's revenue for the quarter was up 152.2% on a year-over-year basis. During the same period last year, the firm earned ($0.04) EPS.
View Xencor's earnings history
.

Who are Xencor's key executives?

Xencor's management team includes the following people:
  • Dr. Bassil I. Dahiyat Ph.D., Co-Founder, CEO, Pres & Director (Age 52, Pay $1.08M)
  • Mr. John J. Kuch, Sr. VP & CFO (Age 63, Pay $648.03k)
  • Dr. John R. Desjarlais, Sr. VP of Research & Chief Scientific Officer (Age 58, Pay $725.03k)
  • Ms. Celia E. Eckert J.D., Sr. VP, Gen. Counsel & Corp. Sec. (Age 49, Pay $600.93k)
  • Dr. Allen S. Yang M.D., Ph.D., Sr. VP & Chief Medical Officer (Age 54, Pay $748.13k)
  • Mr. Charles Liles, Associate Director and Head of Corp. Communications & Investor Relations
  • Ms. Jennifer Sandoz, VP of HR
  • Dr. Jeremy Grunstein Ph.D., Sr. VP of Bus. Devel.
  • Mr. Kirk Rosemark RAC, Sr. VP of Regulatory Affairs & Quality Assurance (Age 57)

What is Bassil I. Dahiyat's approval rating as Xencor's CEO?

6 employees have rated Xencor CEO Bassil I. Dahiyat on Glassdoor.com. Bassil I. Dahiyat has an approval rating of 81% among Xencor's employees.

What other stocks do shareholders of Xencor own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xencor investors own include Intelsat (I), Bank of America (BAC), Apollo Global Management (APO), Cypress Semiconductor (CY), NVIDIA (NVDA), AbbVie (ABBV), Exelixis (EXEL), Intel (INTC), AMC Entertainment (AMC) and Ciena (CIEN).

What is Xencor's stock symbol?

Xencor trades on the NASDAQ under the ticker symbol "XNCR."

How do I buy shares of Xencor?

Shares of XNCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Xencor's stock price today?

One share of XNCR stock can currently be purchased for approximately $28.86.

How much money does Xencor make?

Xencor (NASDAQ:XNCR) has a market capitalization of $1.72 billion and generates $275.11 million in revenue each year. The biopharmaceutical company earns $82.63 million in net income (profit) each year or $1.779990 on an earnings per share basis.

How many employees does Xencor have?

Xencor employs 254 workers across the globe.

How can I contact Xencor?

Xencor's mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The official website for Xencor is www.xencor.com. The biopharmaceutical company can be reached via phone at (626) 305-5900, via email at [email protected], or via fax at 626-305-0350.

This page (NASDAQ:XNCR) was last updated on 7/1/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.